Chemotherapy is an integral part of the present cancer treatment paradigm, despite its common and severe side effects. Nanotechnology provides a plethora of promising avenues for overcoming chemotherapy limitations. Drug encapsulation within nanoparticles helps to retain it in a patient’s body for an extended period, increasing the possibility of it reaching cancer cells. Furthermore, nanoparticles help to decrease some of the ill side effects of chemo by changing the way the drug distributes throughout the body. These considerations led to the creation of the first FDA-approved drug-carrying nanoparticles for cancer treatment: Doxil® or Caelex®, DaunoXome® and Abraxane®. While these nanomedicines have been able to decrease some of the common chemo side effects, drug encapsulation into a nanoparticle did not lead to the impressive improvements in treatment outcomes and many researchers believe that nanomedicine efficacy can be improved even further.

In this review, we highlighted major barriers within the human body that prevent nanoparticles from reaching cancer cells (Fig. 1).  Briefly, once a nanoparticle enters the bloodstream, it is instantly being attacked by the immune cells that recognize it as a foreign object. This results in the majority of the particles being entrapped in the liver and spleen, with only a small percentage left in circulation. Furthermore, even the particles that escaped from the immune system and reached the tumor site need to overcome several local barriers, posed by the abnormal tumor physiology.

Encouraging breakthroughs, however, have been made in the last few years towards the development of new classes of nanoparticles that can respond to the tumor-specific conditions and successfully deliver therapeutics to cancer cells. Concurrently, there is an increasing number of reports describing the use of ‘priming’ strategies that target one or several tumor microenvironment components to enhance the delivery and efficacy of nanomedicines. For example, radiation therapy is often used in the clinic in combination with chemotherapy. Knowing how exactly radiation influences tumor microenvironment can help with the development of optimal combination regimes that will make treatment more effective. Similarly, photodynamic therapy, which relies on the use of a light-activatable molecule and light to kill cancer cells, can be used to make tumors more amenable for nanoparticle accumulation.

This review discusses recent advances in cancer nanomedicine exploiting both nanoparticle design and tumor microenvironment modification (Fig. 2) and provide a critical perspective on the future development of nanomedicine delivery in oncology.

Marta Overchuk ¹, Gang Zheng ^1,2,3
1Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada
²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
³Department of Medical Biophysics, University of Toronto, Canada

Publication

Read offline:     

Related Articles:

	A combined rapid microfluidics and design-of-experiment… Nanomedicine has attracted enormous attention for the introduction of advantageous nanoscale materials. Among them, liposomes have devoted considerable concern owing to unique physicochemical and biological properties, as well as the…
	Nanomaterials as promising alternative in the infection… Nanotechnology offers groundbreaking solutions for the management of infections in the current era when the vast majority of antibiotics has become inefficient. Overcoming antimicrobial resistance and biofilm formation constitute a…
	Fullerene soot nanoparticles impose threat to glial cell… Nanotechnology principally deals with engineering or fine tuning of functional matters at their molecular level. The field has generated an exciting scientific attention globally because of the innumerable possibilities it…
	New antimicrobial strategies against multidrug-resistant… Due to current antibiotic resistance worldwide, there is an urgent need to find new alternative antibacterial approaches capable of dealing with multidrug-resistant pathogens. In fact, the World Health Organization has…
	Epigenetic phenotype diversification helps animals to adapt… There is increasing evidence that epigenetic phenotype variation can contribute to environmental adaptation, speciation and evolution. Epigenetic changes of the phenotype are caused by differences in gene expression rather than…
	Carbapenem-resistant Enterobacteriaceae: fighting mutants Antibiotic resistance occurs when bacteria causing an infection survive after being exposed to a drug that, under normal conditions, would kill it or inhibit its growth. As a result, this…